The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This stock page is the Follow view. The Build view lets your agent query PASG owners, fund changes, insider filings, and source links through REST or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/PASG"
Use Arkolith to show who owns PASG, which funds added or reduced it, and which SEC filings prove each claim.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Vestal Point Capital, LP | $2.4M | 305K | —Held | Q1 2026 | |
| 2 | Eversept Partners, LP | $1.0M | 132K | ▲+4.2% Added · +5K sh | Q1 2026 | |
| 3 | Erste Asset Management GmbH | $527K | 85K | —Held | Q1 2026 | |
| 4 | BOOTHBAY FUND MANAGEMENT, LLC | $148K | 19K | ▲New +19K sh | Q1 2026 | |
| 5 | VANGUARD FIDUCIARY TRUST CO | $134K | 17K | ▲New +17K sh | Q1 2026 | |
| 6 | SBI Securities Co., Ltd. | $973 | 124 | ▼−13% Reduced · −18 sh | Q1 2026 | |
| 7 | CWM, LLC | $8 | 1 | —Held | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Chou William | PRESIDENT AND CEO, Director | Grant (A) | 58K | $0 |
| Mar 16, 2026 | Borthwick Kathleen | CFO | Grant (A) | 16K | $0 |
| Jan 8, 2026 | Chou William | PRESIDENT AND CEO, Director | Option exercise (M) | 10K | $0 |
| Jan 8, 2026 | Chou William | PRESIDENT AND CEO, Director | Option exercise (M) | 10K | — |
| Jan 8, 2026 | Borthwick Kathleen | CFO | Sell (S) | 2K | $38K |
| Jan 8, 2026 | Borthwick Kathleen | CFO | Option exercise (M) | 5K | $0 |
| Jan 8, 2026 | Borthwick Kathleen | CFO | Option exercise (M) | 5K | — |
| Jan 8, 2026 | Chou William | PRESIDENT AND CEO, Director | Sell (S) | 4K | $75K |
| Sep 15, 2025 | Nichols Weston | 10% Owner | Buy (P) | 12K | $83K |
| Sep 12, 2025 | Nichols Weston | 10% Owner | Buy (P) | 20K | $138K |
| Sep 11, 2025 | Nichols Weston | 10% Owner | Buy (P) | 325 | $2K |
| Jul 24, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy (P) | 66K | $379K |
| Company | Co-held by | Combined value |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN | 9 funds | $503.7M |
| BRISTOL-MYERS SQUIBB COBMY | 9 funds | $284.5M |
| REGENERON PHARMACEUTICALSREGN | 9 funds | $199.7M |
| ELI LILLY & COLLY | 8 funds | $1.0B |
| GILEAD SCIENCES INCGILD | 8 funds | $698.0M |
| ABBOTT LABORATORIESABT | 8 funds | $493.8M |
| ELEVANCE HEALTH INCELV | 8 funds | $488.8M |
| UNITED THERAPEUTICS CORPUTHR | 8 funds | $445.2M |
| BOSTON SCIENTIFIC CORPBSX | 8 funds | $442.6M |
| CVS HEALTH CORPCVS | 8 funds | $430.8M |
| REVOLUTION MEDICINES INCRVMD | 8 funds | $319.8M |
| REPLIGEN CORPRGEN | 8 funds | $256.6M |
Ranked by how many of PASG's institutional holders also hold each name, a cross-fund conviction signal. Via the MCP server (ticker.co_held).
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for PASG. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes. Every panel above is one call to the Arkolith API & MCP server.